Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on June 25, 2015, reporting events occurring on June 19, 2015. The filing details significant changes to the company's executive leadership and Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment terms.
- CEO Annual Salary: $390,000
- Equity Grant (Options): 420,000 shares
- Equity Grant (RSUs): 190,000 shares
- Severance (Without Cause): 12 months of salary plus pro-rated target bonus
Material Changes
The primary material change is the appointment of Will McGuire as Chief Executive Officer and President, effective no later than August 18, 2015. Concurrently, Dr. Robert J. Greenberg was appointed Chairman of the Board, and founder Alfred E. Mann was named Chairman Emeritus.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of operational risks. It outlines the terms of the new CEO's employment agreement, including performance-based bonuses, relocation reimbursement, and vesting schedules for equity awards (25% on the first anniversary, followed by quarterly installments).
Investor Verification Checklist
- Verify the official start date of Will McGuire to determine the exact exercise price for the stock options.
- Review the attached Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "without cause" regarding severance.
- Confirm the performance standards and goals established by the Board for Mr. McGuire's bonus eligibility.
- Check subsequent filings for the actual commencement date of the CEO role relative to the August 18, 2015 deadline.